The use of calcitriol and VDRAs should be reserved for people with CKD stages 4 and 5 with severe hyperparathyroidism (ungraded), though the optimal parathyroid hormone (PTH) target is not known in people not on dialysis. This evidence concerns the gene PTH and hyperparathyroidism.